Market Overview

UPDATE: JMP Securities Reiterates On Esperion Therapeutics On Minimal Risks


In a report published Monday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Esperion Therapeutics Inc (NASDAQ: ESPR), and raised the price target from $53.00 to $75.00.

In the report, JMP Securities noted, “The completion of two-year carcinogenicity studies represents a key de-risking milestone for ETC-1002; reiterate our Market Outperform rating and increase our price target from $53 to $75 on Esperion Therapeutics. In our view, there is minimal risk of negative results from the two-year carcinogenicity studies for ETC-1002. Specifically, we believe management received final reports for these studies in 4Q14 and we gain confidence from the lack of disclosure of any unexpected negative findings. We see surpassing this milestone as a key de-risking event for the development of ETC-1002 and look to additional value-driving clinical and regulatory catalysts for the drug candidate in 1H15. We believe these catalysts have the potential to further reinforce the strategic attractiveness of the asset (either in a large pharma partnership or acquisition of the company). Our $75 price target is derived from a risk-adjusted, NPV analysis of ETC-1002.”

Esperion Therapeutics closed on Friday at $41.23.

Latest Ratings for ESPR

Mar 2019JP MorganUpgradesUnderweightNeutral
Dec 2018Goldman SachsInitiates Coverage OnSell
Oct 2018BTIG ResearchInitiates Coverage OnBuy

View More Analyst Ratings for ESPR
View the Latest Analyst Ratings

Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Price Target Analyst Ratings


Related Articles (ESPR)

View Comments and Join the Discussion!

Fiat Chrysler Reports December U.S. Auto Sales Rose 20%

UPDATE: Wunderlich Securities Reiterates On Harvest Natural Resources As Stock Still Has Value